JoAnn A. Giaconi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
JoAnn A. Giaconi has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Simon K. Law
University of California Los Angeles
4 shared publications Anne L. Coleman
University of California at Los Angeles
3 shared publicationsGreet Coppens
University UZ Leuven
2 shared publications- Joseph Caprioli
Glaucoma Division, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
2 shared publications Kuldev Singh
2 shared publicationsReza Bs Kianian
Department of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles
2 shared publications
Latest Publications
- 26 September 2026
- Published by Elsevier in Ophthalmology Glaucoma
Suprachoroidal Glaucoma Surgery: Time for a Fresh Look
- 26 September 2026
- Published by Elsevier in Ophthalmology Glaucoma
Suprachoroidal Glaucoma Surgery: Time for a Fresh Look
- 25 July 2026
- Published by Springer Nature
- p. 39-53
Visual Requirements for Driving in Older Adults with Ocular Diseases
- 25 July 2026
- Published by Springer Nature
- p. 39-53
Visual Requirements for Driving in Older Adults with Ocular Diseases
- 25 July 2026
- Published by Springer Nature
- p. 473-480
Future Research and Direction in Ophthalmology for Older Adults
- 25 July 2026
- Published by Springer Nature
- p. 473-480
Future Research and Direction in Ophthalmology for Older Adults
- 24 November 2023
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 33 (2) , 94-100
Can ChatGPT Aid Clinicians in Educating Patients on the Surgical Management of Glaucoma?
Précis: ChatGPT can help health care providers automate the quality assessment of online health information, but it does not produce easier-to-understand responses compared with existing online health information. Purpose: To compare the readability of ChatGPT-generated health information about glaucoma surgery to existing material online and to evaluate ChatGPT’s ability to analyze the quality of information found online about glaucoma surgery. Methods: ChatGPT was asked to create patient handouts on glaucoma surgery using 7 independent prompts, aiming to generate sixth grade level reading material. Existing patient-targeted online health information about glaucoma surgery was selected from the top 50 search results of 3 search engines, excluding advertisements, blog posts, information intended for health professionals, irrelevant content, and duplicate links. Four validated tools were used to assess readability, and the readability of the ChatGPT-generated material was compared with the readability of existing online information. The DISCERN instrument was used for the quality assessment of online materials. The DISCERN instrument was also programmed to use ChatGPT to evaluate its ability to analyze quality. R software and descriptive statistics were used for data analysis. Results: Thirty-five webpages were included. There was no difference between the reading level of online webpages (12th grade) and the reading level of ChatGPT-generated responses (11th grade), despite the ChatGPT prompts asking for simple language and a sixth grade reading level. The quality of health content was “fair,” with only 5 resources receiving an “excellent” score. ChatGPT scored the quality of health resources with high precision (r=0.725). Conclusions: Patient-targeted information on glaucoma surgery is beyond the reading level of the average patient, therefore at risk of not being understood, and is of subpar quality, per DISCERN tool scoring. ChatGPT did not generate documents at a lower reading level as prompted, but this tool can aid in automating the time-consuming and subjective process of quality assessment.
- 24 November 2023
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 33 (2) , 94-100
Can ChatGPT Aid Clinicians in Educating Patients on the Surgical Management of Glaucoma?
Précis: ChatGPT can help health care providers automate the quality assessment of online health information, but it does not produce easier-to-understand responses compared with existing online health information. Purpose: To compare the readability of ChatGPT-generated health information about glaucoma surgery to existing material online and to evaluate ChatGPT’s ability to analyze the quality of information found online about glaucoma surgery. Methods: ChatGPT was asked to create patient handouts on glaucoma surgery using 7 independent prompts, aiming to generate sixth grade level reading material. Existing patient-targeted online health information about glaucoma surgery was selected from the top 50 search results of 3 search engines, excluding advertisements, blog posts, information intended for health professionals, irrelevant content, and duplicate links. Four validated tools were used to assess readability, and the readability of the ChatGPT-generated material was compared with the readability of existing online information. The DISCERN instrument was used for the quality assessment of online materials. The DISCERN instrument was also programmed to use ChatGPT to evaluate its ability to analyze quality. R software and descriptive statistics were used for data analysis. Results: Thirty-five webpages were included. There was no difference between the reading level of online webpages (12th grade) and the reading level of ChatGPT-generated responses (11th grade), despite the ChatGPT prompts asking for simple language and a sixth grade reading level. The quality of health content was “fair,” with only 5 resources receiving an “excellent” score. ChatGPT scored the quality of health resources with high precision (r=0.725). Conclusions: Patient-targeted information on glaucoma surgery is beyond the reading level of the average patient, therefore at risk of not being understood, and is of subpar quality, per DISCERN tool scoring. ChatGPT did not generate documents at a lower reading level as prompted, but this tool can aid in automating the time-consuming and subjective process of quality assessment.
- 14 July 2022
- Published by Wiley in Optometry and Vision Science
- Vol. 99 (8) , 626-631
Effectiveness of Topical ρ‐Kinase Inhibitors in Veterans with Severe Glaucoma on Maximally Tolerated Medical Therapy
SIGNIFICANCE: The real‐world pharmacological use of netarsudil shows that it can produce a clinically significant decrease in intraocular pressure for a small group of patients, even if they are already taking three or four other hypotensive glaucoma medication classes. PURPOSE: This study aimed to assess the effectiveness of netarsudil in reducing intraocular pressure among veterans with advanced glaucoma on maximally tolerated medical therapy. METHODS: All patients with glaucoma who received netarsudil between June 2018 and April 2020 from the West Los Angeles Veterans Administration Medical Center were reviewed. Inclusion criteria included a minimum of one intraocular pressure measurement in each of two time windows (within and after 4 months of netarsudil use). Exclusion criteria included medication nonadherence, change in treatment plan before post‐treatment intraocular pressure could be obtained, corneal disease precluding reliable measurement, outside follow‐up, and loss to follow‐up. Intraocular pressure at baseline and that at two time windows were compared using analyses of variance. Relationships between intraocular pressure and number of baseline medications and concurrent statin therapy were evaluated. Netarsudil tolerability was reported. RESULTS: Of 200 patients prescribed netarsudil, 42 patients (eyes) met the enrollment criteria. The mean age of these patients was 75.7 years (95% confidence interval [CI], 73.0 to 78.4 years), 64% were of African descent, 79% had open‐angle glaucoma, and the mean number of baseline medications was 3.7 (95% CI, 3.5 to 3.9). Baseline intraocular pressure of 17.2 mmHg (95% CI, 16.1 to 18.2 mmHg) decreased to 15.1 mmHg (95% CI, 14.0 to 16.2 mmHg; P <. 001), and a reduction of >20% was seen in 30.9% of patient after 4 months of netarsudil therapy. Intraocular pressure reduction was not associated with number of baseline medications or systemic statin use. CONCLUSIONS: Netarsudil may produce a clinically significant intraocular pressure reduction in up to a third of the patients with advanced glaucoma already on maximally tolerated medical therapy.
- 14 July 2022
- Published by Wiley in Optometry and Vision Science
- Vol. 99 (8) , 626-631
Effectiveness of Topical ρ‐Kinase Inhibitors in Veterans with Severe Glaucoma on Maximally Tolerated Medical Therapy
SIGNIFICANCE: The real‐world pharmacological use of netarsudil shows that it can produce a clinically significant decrease in intraocular pressure for a small group of patients, even if they are already taking three or four other hypotensive glaucoma medication classes. PURPOSE: This study aimed to assess the effectiveness of netarsudil in reducing intraocular pressure among veterans with advanced glaucoma on maximally tolerated medical therapy. METHODS: All patients with glaucoma who received netarsudil between June 2018 and April 2020 from the West Los Angeles Veterans Administration Medical Center were reviewed. Inclusion criteria included a minimum of one intraocular pressure measurement in each of two time windows (within and after 4 months of netarsudil use). Exclusion criteria included medication nonadherence, change in treatment plan before post‐treatment intraocular pressure could be obtained, corneal disease precluding reliable measurement, outside follow‐up, and loss to follow‐up. Intraocular pressure at baseline and that at two time windows were compared using analyses of variance. Relationships between intraocular pressure and number of baseline medications and concurrent statin therapy were evaluated. Netarsudil tolerability was reported. RESULTS: Of 200 patients prescribed netarsudil, 42 patients (eyes) met the enrollment criteria. The mean age of these patients was 75.7 years (95% confidence interval [CI], 73.0 to 78.4 years), 64% were of African descent, 79% had open‐angle glaucoma, and the mean number of baseline medications was 3.7 (95% CI, 3.5 to 3.9). Baseline intraocular pressure of 17.2 mmHg (95% CI, 16.1 to 18.2 mmHg) decreased to 15.1 mmHg (95% CI, 14.0 to 16.2 mmHg; P <. 001), and a reduction of >20% was seen in 30.9% of patient after 4 months of netarsudil therapy. Intraocular pressure reduction was not associated with number of baseline medications or systemic statin use. CONCLUSIONS: Netarsudil may produce a clinically significant intraocular pressure reduction in up to a third of the patients with advanced glaucoma already on maximally tolerated medical therapy.
- Open Access
- 1 December 2020
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 20, 100968
Clinical manifestations of intravitreal bortezomib injection
- 1 December 2020
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 20, 100968
Open AccessClinical manifestations of intravitreal bortezomib injection
- 1 January 2020
- Published by Elsevier in Ophthalmology Glaucoma
- Vol. 3 (1) , 1-6
American Glaucoma Society Position Paper: Microinvasive Glaucoma Surgery
- 1 January 2020
- Published by Elsevier in Ophthalmology Glaucoma
- Vol. 3 (1) , 1-6
American Glaucoma Society Position Paper: Microinvasive Glaucoma Surgery
- Open Access
Comparison of Outcomes between Endoscopic and Transcleral Cyclophotocoagulation
Importance: Traditionally cyclophotocoagulation has been reserved as a treatment of last resort for eyes with advanced stage glaucoma, but increasingly it is offered to eyes with less severe disease. Endoscopic approaches in particular are utilized in increasing numbers of patients despite only a small number of publications on its results. Objective: The purpose of this study was to compare the efficacy and safety of endoscopic and transcleral cyclophotocoagulation (ECP and TCP) procedures in eyes with refractory glaucomas. Design, Setting, and Participants: A chart review was performed on consecutive patients who underwent ECP and TCP at a tertiary ophthalmology care center between January 2000 and December 2010. Cases with fewer than 3 months of follow-up or that had concurrent pressure reducing procedures were excluded. The main outcome measures examined were intraocular pressure (IOP), number of glaucoma medications, best corrected visual acuity (BCVA), additional glaucoma procedure required, and complications. Main Outcomes and Measures: Forty-two eyes (42 patients) that underwent ECP and forty-four eyes (44 patients) that underwent TCP were identified. The TCP group had a statistically higher mean age (71.2 ± 16.7 vs. 58.1 ± 22.9 years, respectively), larger proportion of neovascular glaucoma (40.9% vs. 16.7%), worse initial BCVA (logMAR 2.86 vs. 1.81), and higher preoperative IOP (45.3 vs. 26.6 mmHg) than the ECP group. At 12 months follow-up, the mean IOP difference between groups was not statistically significant, although the change in IOP from baseline to 12 months was greater for the TCP group (p = 0.006). The rates of progression to no light perception (NLP) and phthisis bulbi were significantly higher amongst TCP eyes than ECP eyes (27.2% vs. 4.8%, p = 0.017, and 20.5% vs. 0%, p = 0.003, respectively). Of these eyes that progressed, a majority had neovascular glaucoma (NVG). Corneal decompensation was the most frequent complication following ECP (11.9%). Conclusions and Relevance: In patients with preoperative BCVA of 20/400 or better, overall complication rates (cystoid macular edema, exudative retinal detachment, inflammation, cornea decompensation) were higher after ECP than with TCP. In refractory glaucomas in a real world setting (not a trial), TCP was more frequently used in ischemic eyes. TCP was associated with a higher rate of progression to phthisis bulbi and loss of light perception than ECP. However, ECP was associated with a clinically significant rate of corneal decompensation. These outcomes likely were related to the severity of underlying ocular diseases found in these eyes.
Open AccessComparison of Outcomes between Endoscopic and Transcleral Cyclophotocoagulation
Importance: Traditionally cyclophotocoagulation has been reserved as a treatment of last resort for eyes with advanced stage glaucoma, but increasingly it is offered to eyes with less severe disease. Endoscopic approaches in particular are utilized in increasing numbers of patients despite only a small number of publications on its results. Objective: The purpose of this study was to compare the efficacy and safety of endoscopic and transcleral cyclophotocoagulation (ECP and TCP) procedures in eyes with refractory glaucomas. Design, Setting, and Participants: A chart review was performed on consecutive patients who underwent ECP and TCP at a tertiary ophthalmology care center between January 2000 and December 2010. Cases with fewer than 3 months of follow-up or that had concurrent pressure reducing procedures were excluded. The main outcome measures examined were intraocular pressure (IOP), number of glaucoma medications, best corrected visual acuity (BCVA), additional glaucoma procedure required, and complications. Main Outcomes and Measures: Forty-two eyes (42 patients) that underwent ECP and forty-four eyes (44 patients) that underwent TCP were identified. The TCP group had a statistically higher mean age (71.2 ± 16.7 vs. 58.1 ± 22.9 years, respectively), larger proportion of neovascular glaucoma (40.9% vs. 16.7%), worse initial BCVA (logMAR 2.86 vs. 1.81), and higher preoperative IOP (45.3 vs. 26.6 mmHg) than the ECP group. At 12 months follow-up, the mean IOP difference between groups was not statistically significant, although the change in IOP from baseline to 12 months was greater for the TCP group (p = 0.006). The rates of progression to no light perception (NLP) and phthisis bulbi were significantly higher amongst TCP eyes than ECP eyes (27.2% vs. 4.8%, p = 0.017, and 20.5% vs. 0%, p = 0.003, respectively). Of these eyes that progressed, a majority had neovascular glaucoma (NVG). Corneal decompensation was the most frequent complication following ECP (11.9%). Conclusions and Relevance: In patients with preoperative BCVA of 20/400 or better, overall complication rates (cystoid macular edema, exudative retinal detachment, inflammation, cornea decompensation) were higher after ECP than with TCP. In refractory glaucomas in a real world setting (not a trial), TCP was more frequently used in ischemic eyes. TCP was associated with a higher rate of progression to phthisis bulbi and loss of light perception than ECP. However, ECP was associated with a clinically significant rate of corneal decompensation. These outcomes likely were related to the severity of underlying ocular diseases found in these eyes.
- 8 July 2016
- Published by Springer Nature
- p. 339-347
Procedural Treatments: Bleb Needling
- 8 July 2016
- Published by Springer Nature
- p. 471-480
Pediatric Glaucoma: IOP, Axial Length, and Surgery Indications
- 8 July 2016
- Published by Springer Nature
- p. 471-480
Pediatric Glaucoma: IOP, Axial Length, and Surgery Indications